The class 1 BRAF V600E mutation and also class 2 mutations allow for constitutive activation of the pathway; therefore, a concurrent KRAS mutation is redundant which is indicated by the mutual exclusivity of these two mutation types occurring in a single cancer [1, 29]. The gene discussed is BRAF; the disease is cancer.